These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16123717)

  • 21. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
    Watt KD; Lyden ER; Gulizia JM; McCashland TM
    Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study.
    Guerrero RB; Batts KP; Burgart LJ; Barrett SL; Germer JJ; Poterucha JJ; Wiesner RH; Charlton MR; Persing DH
    Mod Pathol; 2000 Mar; 13(3):229-37. PubMed ID: 10757333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients.
    Stehman-Breen CO; Psaty BM; Emerson S; Gretch D; Bronner M; Marsh C; Davis CL
    Transplantation; 1997 Jul; 64(2):281-6. PubMed ID: 9256188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus recurrence after liver transplantation: biomarkers of disease and fibrosis progression.
    Maluf DG; Archer KJ; Villamil F; Stravitz RT; Mas V
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):445-58. PubMed ID: 20678018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In situ enzymatic oligonucleotide amplification of hepatitis C virus-RNA in liver biopsy specimens (reverse transcriptase in situ polymerase chain reaction) after orthotopic liver transplantation for hepatitis C-related liver disease.
    Fragulidis GP; Cirocco RE; Weppler D; Berho M; Gillian G; Markou M; Viciana A; Esquenazi V; Nery JR; Miller J; Reddy KR; Tzakis AG
    Transplantation; 1998 Dec; 66(11):1472-6. PubMed ID: 9869088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts.
    Tao R; Ruppert K; Cruz RJ; Malik SM; Shaikh O; Ahmad J; DiMartini A; Humar A; Fontes PA; de Vera ME
    Liver Transpl; 2010 Nov; 16(11):1288-95. PubMed ID: 21031544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation.
    Iacob S; Cicinnati VR; Hilgard P; Iacob RA; Gheorghe LS; Popescu I; Frilling A; Malago M; Gerken G; Broelsch CE; Beckebaum S
    Transplantation; 2007 Jul; 84(1):56-63. PubMed ID: 17627238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients.
    Takada Y; Haga H; Ito T; Nabeshima M; Ogawa K; Kasahara M; Oike F; Ueda M; Egawa H; Tanaka K
    Transplantation; 2006 Feb; 81(3):350-4. PubMed ID: 16477219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation.
    Saab S; Chang AJ; Comulada S; Geevarghese SK; Anselmo RD; Durazo F; Han S; Farmer DG; Yersiz H; Goldstein LI; Ghobrial RM; Busuttil RW
    Liver Transpl; 2003 Oct; 9(10):1053-61. PubMed ID: 14526400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Belli LS; Burroughs AK; Burra P; Alberti AB; Samonakis D; Cammà C; De Carlis L; Minola E; Quaglia A; Zavaglia C; Vangeli M; Patch D; Dhillon A; Cillo U; Guido M; Fagiuoli S; Giacomoni A; Slim OA; Airoldi A; Boninsegna S; Davidson BR; Rolles K; Pinzello G
    Liver Transpl; 2007 May; 13(5):733-40. PubMed ID: 17370330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of antiviral treatment on survival in HCV-positive liver recipients.
    Wawrzynowicz-Syczewska M; Zeair S; Andruszkiewicz A; Bartoszewicz K; Sławiński J; Laurans Ł; Jurczyk K; Karpińska E; Socha Ł; Duczkowska M; Parczewski M
    Ann Transplant; 2014 Jul; 19():367-72. PubMed ID: 25073736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up.
    Neumann UP; Berg T; Bahra M; Puhl G; Guckelberger O; Langrehr JM; Neuhaus P
    Transplantation; 2004 Jan; 77(2):226-31. PubMed ID: 14742986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
    Neumann UP; Berg T; Bahra M; Seehofer D; Langrehr JM; Neuhaus R; Radke C; Neuhaus P
    J Hepatol; 2004 Nov; 41(5):830-6. PubMed ID: 15519657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis.
    Berenguer M; Prieto M; Palau A; Rayón JM; Carrasco D; Juan FS; López-Labrador FX; Moreno R; Mir J; Berenguer J
    Liver Transpl; 2003 Mar; 9(3):228-35. PubMed ID: 12619018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
    García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
    Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts.
    Hernandez-Alejandro R; Croome KP; Quan D; Mawardi M; Chandok N; Dale C; McAlister V; Levstik MA; Wall W; Marotta P
    Transplantation; 2011 Sep; 92(6):686-9. PubMed ID: 21832962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.